clinical

Articles

Improvement in visual acuity, central retinal thickness, vitreous haze reported at 6 months

Tocilizumab effective for managing posterior segment inflammation

Intravitreal triamcinolone acetonide, dexamethasone implant superior for regional treatment of disorder

Managing uveitic macular edema

Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.

Understanding etiology crucial for appropriate uveitic treatment

IL-6 inhibition shows promise as treatment for non-infectious uveitis

Novel local corticosteroid therapy shows positive efficacy signals, favorable safety profile says Rahul Khurana, MD.

Data promising in uveitic macular edema pivotal trial 

Adalimumab therapy safe, effective in real-world, open-label uveitis study

Uveitis does not have to be vexing. Here are some basic principles to make it easier for ophthalmologists to identify the disorder, says James Philip Dunn Jr., MD

Pearls for better uveitis workups

Intravitreal sirolimus 400 mcg (Ospiria, Santen) demonstrated positive results in pivotal trials investigating it as a treatment for non-infectious uveitis of the posterior segment. A New Drug Application is under FDA review.

Sirolimus shows promise for posterior segment non-infectious uveitis

Local therapy plays a significant role in the treatment of uveitis, either as monotherapy or in combination therapy. Alongside a number of pharmacotherapeutic agents, new products and technologies are in development that could expand clinicians’ options and improve outcomes.

New and different therapies emerging through uveitis pipeline

Results from the Study Assessing double-masKed Uveitis tREAtrement (SAKURA) program support the efficacy and safety of intravitreal sirolimus 440 mcg (Opsiria, Santen) for treating noninfectious uveitis of the posterior segment, said Pauline T. Merrill, MD.